Abstract
Herein, we describe a case of early belatacept conversion in a human immunodeficiency virus (HIV)-positive kidney transplant recipient in an effort to improve suboptimal graft function and avoid drug interactions following anti-thymocyte globulin (ATG) administration. We observed improvement in renal function without HIV disease progression or opportunistic infections. Donor-specific antibodies appeared shortly after conversion but cleared without intervention. This case highlights belatacept as a means to improve renal function and avoid significant drug interactions even following ATG induction.
Original language | English (US) |
---|---|
Article number | e12748 |
Journal | Transplant Infectious Disease |
Volume | 19 |
Issue number | 5 |
DOIs | |
State | Published - Oct 1 2017 |
Keywords
- belatacept
- HIV
- human immunodeficiency virus
- kidney transplantation
ASJC Scopus subject areas
- Transplantation
- Infectious Diseases